Anika therapeutics, inc. revises earnings guidance for the year 2019

Anika therapeutics, inc. revised earnings guidance for the year 2019. based on currently available information, the company expects total revenue growth to be in the range of 6% to 7% for the full year of 2019. the company anticipated u.s. gaap net income in the mid- to high-$20 million range.

ANIK Ratings Summary

ANIK Quant Ranking